Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority…

By M. Rummel, N. Niederle, G. Maschmeyer, G. Banat, U. V. Grünhagen, C. Losem, D. Kofahl-Krause, G. Heil, M. Welslau, C. Balser and 10 more. The Lancet, 2013

1,406 citations recorded by the source corpus.

Subfields: Dermatology, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/c6a451dc67118286212b983f6ac891561aa0279d